Alzamend Neuro Inc.
13F holders, Q1 2025 (March 31)11holders −6
1new positions
7sold out
$0.95avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Alzamend Neuro Inc. in their 13F filings, down 6 from Q4 2024. 1 opened new positions and 7 sold out. The largest holders were Geode Capital Management, LLC ($37K), Truist Financial Corp. ($15K) and Barclays PLC ($4K).
- Company
- Alzamend Neuro Inc.
- CUSIP
- 02262M506
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 7 | $70K |
All 13F filers, Q4 2024 → Q1 2025: 9,997 shares bought and 60,115 shares sold, net −50,118 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | Add +16.7% | 39,152 | $37K |
| Truist Financial Corp. | 0.00% | No change | 15,498 | $15K |
| Barclays PLC | 0.00% | New | 4,375 | $4K |
| BlackRock, Inc. | 0.00% | No change | 3,973 | $4K |
| Bank of America Corp. | 0.00% | Add +7.3% | 146 | $139 |
| Harbor Investment Advisory, LLC | 0.00% | No change | 20 | $19 |
| Activest Wealth Management | 0.00% | No change | 20 | $19 |
| SBI Securities Co., Ltd. | 0.00% | No change | 18 | $17 |
| City State Bank | 0.00% | No change | 4 | $4 |
| Morgan Stanley | 0.00% | No change | 3 | $3 |
| Parallel Advisors, LLC | 0.00% | No change | 3 | $3 |
"% of holder's portfolio" is ALZAMEND NEURO INC's weight in each manager's 13F, not the share of Alzamend Neuro Inc. the manager owns.